Ceylan, BahadırArslan, FerhatBatırel, AyşeFincancı, MuzafferYardımcı, CemFersan, EsraPaşaoğlu, EsraYılmaz, MesutMert, Ali08.07.20192019-07-0808.07.20192019-07-082016Ceylan, B., Arslan, F., Batırel, A., Fincancı, M., Yardımcı, C., Fersan, E. ... Mert, A. (2016). Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turkish Journal of Gastroenterology, 27(1), 42-46. https://dx.doi.org/10.5152/tjg.2015.1503481300-4948https://hdl.handle.net/20.500.12511/482https://dx.doi.org/10.5152/tjg.2015.150348Background/Aims: We aimed to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on viral kinetics and virologic response to tenofovir and entecavir treatment in patients with chronic hepatitis B virus (HBV) infection.Materials and Methods: This study was designed as a retrospective multicenter cohort study. The impact of hepatosteatosis on pre-treatment serum HBV DNA levels and also on the virologic response to either tenofovir or entecavir at 6 and 12 months of therapy was investigated. Results: A total of 145 cases were involved in the study [median age 40 (18-73) years, 90 (62%) males]. In multivariate analysis, it was detected that patients with NAFLD were older and had a higher body mass index (BMI) [Odds ratio (95% confidence interval) and p-value for age were 1.040 (1.003-1.079) and 0.033 and for BMI were 1.348 (1.190-1.528) and 0.0001, respectively]. When only the 43 patients who were younger than 35.5 years old and who had a BMI less than 27.59 were investigated, serum high-density lipoprotein (HDL) levels and serum HBV DNA levels were lower in patients with NAFLD in multivariate analysis [Odds ratio (95% confidence interval) and p-values for serum HDL level and HBV DNA level were 0.864 (0.061-0.980) and 0.023 and 0.995 (0.990-0.999) and 0.025, respectively]. Totally, 57 and 75 of the patients had received entecavir and tenofovir, respectively. Conclusion: Viral replication decreases in patients with chronic HBV infection in the presence of NAFLD, and NAFLD had no impact on the virologic response to entecavir and tenofovir treatmenteninfo:eu-repo/semantics/openAccessEntecavirFatty LiverHepatitis B VirusArticle2714246Q4Q3